Ingmar Gorman, PhD, is chief executive officer and cofounder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike.
Dr. Gorman served as site co-principal investigator on an FDA-approved Phase 3 clinical trial of MDMA-Assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA-approved clinical trial of psilocybin for treatment-resistant depression.
Dr. Gorman received his clinical training in New York City at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University. He has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.